REMARKS

This application contained claims 1-415, the status of which is as follows:

- (a) Claims 1, 9-12, 17, 26, 29, 31, 37-41, 45-46, 54, 57-58, 67-76, 79-80, 131-140, and 143-144 are as originally filed.
- (b) Claim 3 has been currently amended to correct a typographical error.
- (c) Claims 2, 4-8, 13-16, 18-25, 27-28, 30, 32-36, 42-44, 47-53, 55-56, 59-66, 77-78, 81-130, 141-142, and 145-406 have been canceled without prejudice. The Applicant intends to prosecute these claims in a continuation application.
 - (d) Claims 407-415 are new.

No new matter has been added.

The Applicant is filing, on even date herewith, a petition pursuant to MPEP Section 708.02 VIII to accelerate examination of the above-referenced patent application.

Claims 407-415 are new. These new claims are supported in the Applicant's specification as follows. It is noted that only a single reference in the specification is provided, even for claims which find support in multiple references in the specification.

New claim(s)	Applicant's specification
407 ("to configure the current	"In preferred embodiments of the present
so as to facilitate uptake,	invention, an electrical stimulator drives
through the BBB, of a	current into the sphenopalatine ganglion
therapeutic agent for treating a	(SPG) or into neural tracts originating or
medical condition, when the	reaching the SPG. Typically, the stimulator
permeability of the BBB is	drives the current in order to control and/or
increased")	modify SPG-related behavior, e.g., in order
410 ("administering, to a	to induce changes in cerebral blood flow
systemic blood circulation of	and/or to modulate permeability of the blood-
the patient, a therapeutic agent for treating a medical condition")	brain barrier (BBB). These embodiments
	may be used in many medical applications,
	such as, by way of illustration and not
	limitation (c) the facilitation of drug
	transport across the BBB" (page 8,
	paragraph [0030]).
408, 414 ("the condition	"In general, it is believed that substantially all
includes a brain tumor")	pharmacological treatments aimed at
	cerebral cells for neurological and
	psychiatric disorders are amenable for use
	with these embodiments of the present
	invention. In particular, these embodiments
	may be adapted for use in the treatment of

disorders such as brain tumors. . ." (page 12, paragraph [0041]).

409 ("the drug includes large pharmaceutical molecules selected from the list consisting of: hydrophilic molecules having a molecular weight of greater than about 200 Da, and lipophilic molecules having a molecular weight of greater than about 500 Da")

413 ("the therapeutic agent includes large pharmaceutical molecules selected from the list consisting of: hydrophilic molecules having a molecular weight of greater than about 200 Da, and lipophilic molecules having a molecular weight of greater than about 500 Da")

"The passage of certain molecules from cerebral blood vessels into the brain is hindered by the BBB. The endothelium of the capillaries, the plasma membrane of the blood vessels, and the foot processes of the astrocytes all impede uptake by the brain of the molecules. The BBB generally allows only small molecules (e.g., hydrophilic molecules of molecular weight less than about 200 Da, and lipophilic molecules of less than about 500 Da) to pass from the circulation into the brain.

"In accordance with a preferred embodiment of the present invention, parasympathetic activation induced by current from stimulator 4 overcomes the resistance to trans-BBB molecular movement generated by the endothelium of the cerebral capillaries and the plasma membrane. For some applications, therefore, stimulator 4 may be used to transiently remove a substantial

	used to transiently remove a substantial
	obstacle to the passage of drugs from the
	blood to the brain" (page 24, paragraph
	[0080] – page 25, paragraph [0081]).
411 ("commencing	"In this embodiment, a drug is administered
administration of the	to the patient at a constant rate, e.g.,
therapeutic agent prior to	intravenously, prior to the initiation of
initiating the application of the	stimulation of the SPG at time T1" (page 33,
current")	paragraph [0097]).
412 ("administering the	"Alternatively, for some applications it is
therapeutic agent shortly after	desirable to give a single injection of a bolus
initiating the application of the	of the drug shortly before or after initiation of
current")	stimulation of the SPG" (page 34, paragraph
	[0097]).
415 ("the therapeutic agent	"Embodiments of the present invention have
includes a chemotherapeutic	many medical applications. For example,
drug")	chemotherapeutic drugs need to pass into
	cerebral tissue in order to treat brain tumors"
	(page 42, paragraph [0110]).
	

Notice of allowance of the present application is respectfully requested.

Appln. No. 10/753,882 Amd. dated May 13, 2004

If the Examiner has any questions he is invited to contact the undersigned at 202-628-5197.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant

Registration No. 31,979

RSJ:ft

Telephone No.: (202) 628-5197 Facsimile No.: (202) 737-3528
G:\BN\C\colb\Shalev2A\Pto\13May04PrelimAmdt.doc